Detrenis Simona, Meschi Michele, del Mar Jordana Sanchez Maria, Savazzi Giorgio
Department of Internal Medicine and Nephrology, University of Parma, Italy.
J Urol. 2007 Oct;178(4 Pt 1):1164-70. doi: 10.1016/j.juro.2007.05.133. Epub 2007 Aug 14.
Contrast medium induced nephropathy is the third cause of in-hospital acute renal failure. The first studies in this area were done with reference to urological practice only. Although various guidelines on the management of contrast medium induced nephropathy were provided by the European Society of Urogenital Radiology, more recently many investigators have focused their attention on contrast medium use in interventional vascular radiology and cardiology. We critically reviewed the literature to clarify the impact of contrast medium induced nephropathy in urology and the possible prophylactic measures against it.
A MEDLINE/PubMed, EMBASE and Cochrane Library search for 1971 to 2006 was performed. All articles related to the use of contrast medium in urological practice and contrast medium induced nephropathy were reviewed.
Many pathological conditions frequently seen by urologists are diagnosed by imaging requiring contrast medium. A basic understanding of the risk factors for contrast medium induced nephropathy and the strategies for its prevention are useful to prepare urological patients for these procedures. Prophylaxis includes the discontinuation of potentially nephrotoxic drugs and the use of protocols for periprocedural hydration.
The general approach to the recognition and prevention of contrast medium induced nephropathy in patients at risk should be extended to urological clinical practice since no definitive evidence based data are available regarding contrast medium induced nephropathy management in urological patients. Moreover, these patients can frequently present with the most significant risk factor for contrast medium mediated kidney damage, that is preexisting acute or chronic renal failure. Controlled trials are needed to establish the incidence of contrast medium induced nephropathy in diagnostic or interventional procedures in uroradiology.
造影剂诱发的肾病是住院患者急性肾衰竭的第三大病因。该领域最初的研究仅针对泌尿外科实践。尽管欧洲泌尿生殖放射学会提供了关于造影剂诱发肾病管理的各种指南,但最近许多研究人员将注意力集中在介入血管放射学和心脏病学中造影剂的使用上。我们对文献进行了批判性综述,以阐明造影剂诱发肾病在泌尿外科中的影响以及针对它的可能预防措施。
对1971年至2006年期间的MEDLINE/PubMed、EMBASE和Cochrane图书馆进行检索。对所有与泌尿外科实践中造影剂使用及造影剂诱发肾病相关的文章进行了综述。
泌尿外科医生常见的许多病理状况需借助使用造影剂的影像学检查来诊断。对造影剂诱发肾病的危险因素及预防策略有基本了解,有助于为泌尿外科患者接受这些检查做好准备。预防措施包括停用潜在的肾毒性药物以及采用围手术期水化方案。
由于目前尚无关于泌尿外科患者造影剂诱发肾病管理的确切循证数据,因此对于高危患者识别和预防造影剂诱发肾病的一般方法应推广至泌尿外科临床实践。此外,这些患者常存在造影剂介导肾损伤的最显著危险因素——即已存在的急性或慢性肾衰竭。需要进行对照试验以确定泌尿放射学诊断或介入操作中造影剂诱发肾病的发生率。